FDA label
What is Uptravi used for?
Uptravi contains selexipag. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Uptravi lists this use: Pulmonary Arterial Hypertension.
Run it in Rivvi
Which 2027 plans near you dropped or restricted Uptravi?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Uptravi, tablet, coated
Indications and Usage, quoted from the label by Actelion Pharmaceuticals US, Inc. (NDA207947). Cross-references to other label sections are left out.
Pulmonary Arterial Hypertension
Adult Patients
UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms.
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%).
Pediatric Patients
UPTRAVI is indicated for the treatment of PAH (WHO Group I) in pediatric patients aged two years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.
Source: DailyMed label, set id a7a23b87-f892-4e2c-8e2e-ebf841220f90, version 26, effective May 28, 2026. NDC 66215-602, one of 8 listings for this product.
Questions
What is Uptravi used for?
The FDA label for Uptravi lists this use: Pulmonary Arterial Hypertension.
What drug class is Uptravi?
FDA lists selexipag in the Prostacyclin Receptor Agonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.